Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis.
The purpose of this study carried out in Iranian Azerbaijan was to determine the pattern of skin-test positivity to mycobacterial antigens in children living in the valley, and to assess the effect on this of a series of vaccines against mycobacterial disease. Set up in 1978, 1707 tuberculin-negative children without scars of previous BCG vaccination were vaccinated with BCG Glaxo alone (vaccine A) or with the addition of a suspension of killed Mycobacterium vaccae (vaccine B). One hundred children were vaccinated with BCG Glaxo plus a suspension of M. leprae (vaccine C). Eight to 10 years later about half of the children were found for follow up. At this time further children were skin tested, and the results obtained were related to whether or not they had scars of vaccination with BCG Pasteur (Teheran) given by the local health authorities. Between setting up the study and the first follow up, cases of leprosy or tuberculosis had occurred in some of the villages, although not among those we had vaccinated. Differences between the effects of the vaccines were only found in villages with cases of leprosy. In these villages positivity to leprosin A was significantly greater after vaccine B (49%) than after vaccine A (36%; p less than 0.04). The results for scrofulin and vaccine were the same after both vaccines, and significantly lower than in the villages without cases of leprosy. The general reduction in skin-test positivity in the villages with leprosy cases was mainly due to a loss of category 1 responders to group i, common mycobacterial, antigens. It was concluded that where casual contact with cases of leprosy occurs the combination of BCG with killed M. vaccae is likely to be a better vaccine for leprosy than is BCG alone. Although few children received the combination with M. leprae, the results obtained were not particularly promising.
Ghazi Saidi
K
K
School of Public Health, University of Teheran, Iran.
Stanford
J L
JL
Stanford
C A
CA
Dowlati
Y
Y
Farshchi
Y
Y
Rook
G A
GA
Rees
R J
RJ
D000293:Adolescent; D000942:Antigens, Bacterial / Q000276:immunology; D001500:BCG Vaccine / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007492:Iran; D007918:Leprosy / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control; D009166:Mycobacterium leprae / Q000276:immunology; D012882:Skin Tests; D014374:Tuberculin Test; D014376:Tuberculosis / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control; D014611:Vaccination
D000942:Antigens, Bacterial; D001500:BCG Vaccine; C041383:leprosin A